The Experts below are selected from a list of 111 Experts worldwide ranked by ideXlab platform
Yang Man - One of the best experts on this subject based on the ideXlab platform.
-
The Clinic Analysis of 32 Patients with Premature Ovarian Failure
Journal of Kunming Medical University, 2010Co-Authors: Yang ManAbstract:Objective To analyze the clinic data of patients with premature ovarian failure(POF),investigate the therapy of premature ovarian failure,recognize POF further and attach importance to it.Methods 32 patients with premature ovarian failure from October 1999 to October 2006 were recruited in our study.Their clinic data and therapy were analyzed retrospectively.Results The circulating concentration of sex hormone in the patients with POF:1)estradiol(E2)level was below or equal to E2 level in follicular phase,Follicle-stimulating hormone(FSH)level and Luteinizing hormone(LH)level significantly increased,Prolactin(PRL)level was normal.The patients with POF suffered from abnormal emotions,the genital and Breast Atrophy at different degree,the loss of bone and osteoporosis.Through the rational hormone replacement,the patients'clinic symptoms were improved,but the complete recovery was difficult.Conclusion The pathogenesis of POF is complex,the therapy is difficult and the recovery rate is low,therefore,POF deserves to study and importance should be attached to it.
Giuseppe Sanguineti - One of the best experts on this subject based on the ideXlab platform.
-
Impact of Sequencing Radiation Therapy and Chemotherapy on Long-Term Local Toxicity for Early Breast Cancer: Results of a Randomized Study at 15-Year Follow-Up
International journal of radiation oncology biology physics, 2016Co-Authors: Paola Pinnarò, Carolina Giordano, Alessia Farneti, Lidia Strigari, Valeria Landoni, Laura Marucci, Maria Grazia Petrongari, Giuseppe SanguinetiAbstract:Purpose To compare long-term late local toxicity after either concomitant or sequential chemoradiation therapy after Breast-conserving surgery. Methods and Materials From 1997 to 2002, women aged 18 to 75 years who underwent Breast-conserving surgery and axillary dissection for early Breast cancer and in whom CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) chemotherapy was planned were randomized between concomitant and sequential radiation therapy. Radiation therapy was delivered to the whole Breast through tangential fields to 50 Gy in 20 fractions over a period of 4 weeks, followed by an electron boost. Surviving patients were tentatively contacted and examined between March and September 2014. Patients in whom progressive disease had developed or who had undergone further Breast surgery were excluded. Local toxicity (fibrosis, telangiectasia, and Breast Atrophy or retraction) was scored blindly to the treatment received. A logistic regression was run to investigate the effect of treatment sequence after correction for several patient-, treatment-, and tumor-related covariates on selected endpoints. The median time to cross-sectional analysis was 15.7 years (range, 12.0-17.8 years). Results Of 206 patients randomized, 154 (74.8%) were potentially eligible. Of these, 43 (27.9%) refused participation and 4 (2.6%) had been lost to follow-up, and for 5 (3.2%), we could not restore planning data; thus, the final number of analyzed patients was 102. No grade 4 toxicity had been observed, whereas the number of grade 3 toxicity events was low ( P =.013) and the SOMA (Subjective, Objective, Management and Analytic) scale (OR, 3.75; 95% CI, 1.19-11.79; P =.018), as well as grade 2 or 3 Breast Atrophy or retraction (OR, 3.87; 95% CI, 1.42-10.56; P =.008). No effect on telangiectasia was detected. Conclusions At long-term follow-up, concomitant chemoradiation therapy has a detrimental effect on both fibrosis and retraction with an approximately 4-fold increase in the odds of grade 2 or 3 toxicity.
G. Calais - One of the best experts on this subject based on the ideXlab platform.
-
Impact on the cosmetic outcome of concurrent administration of adjuvant chemotherapy and radiotherapy after Breast-conservative surgery: differences between patient's and doctor's views.
2006Co-Authors: A. Toledano, P. Garaud, D. Serin, A. Fourquet, Jf. Bosset, Noel Breteau, G. Body, David Azria, I. Suzanne, G. CalaisAbstract:Purpose: A multicenter randomized study comparing after Breast-conservative surgery, sequential versus concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) was initiated (ARCOSEI). After a median follow-up of 6.7 (4.3-9) years, we assessed prospectively late effects and cosmesis satisfaction of these two strategies. Methods and material: After Breast-conserving surgery, patients were treated either with sequential treatment with CT first followed by RT (arm A) or CT administered concurrently with the same normofractinnated Breast RT (arm B).With structured questions, 214 patients (107 in each arm) rated their satisfaction considering cosmesis, the difference in overall appearance, and specific changes of the Breast. Late toxicity (LENT/SOMA scale) and cosmesis were blinded to treatment and assessed by a radiation oncologist by a qualitative scale and another semi-qualitative and semi-quantitative evaluation. Results: Subcutaneous fibrosis (SF), telangectasia (T), skin pigmentation (SP), and Breast Atrophy (BA) were significantly increased in arm B. Patient's cosmesis satisfaction was not statistically different between the two arms with 92.6% of good results in arm A and 86% in arm B (p=0.72); although patients have found more important differences in the treated Breast in arm B than in arm A, with 28.8% vs 14.3% of bad results, respectively. Physician's prospective assessment found less favorable cosmesis results with concomitant treatment than with sequential one, with 40% and 15% of unsatisfaction, respectively (p=0.0014) using a semi-quantitative and qualitative scale; The use of a subjective 5-point scale found also a worse physician's cosmesis satisfaction in arm B than in arm A (p=0.0013) Conclusion: The concurrent use of CT with RT is significantly associated with an increase incidence of grade 2 or greater late side effects. Rating of cosmesis is also subjective. Patients' satisfaction with cosmesis is greater than the doctors' for concomitant radiochemotherapy in Breast cancer, and is not only determined by radiation late effects. With two methods, physician found a worse cosmesis outcome for concomitant radiochemotherapeutic
-
Concurrent administration of adjuvant chemotherapy and radiotherapy after Breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
International journal of radiation oncology biology physics, 2006Co-Authors: A. Toledano, P. Garaud, D. Serin, A. Fourquet, Jf. Bosset, Noel Breteau, G. Body, David Azria, Olivier Le Floch, G. CalaisAbstract:Purpose: In 1996, a multicenter randomized study was initiated that compared sequential vs. concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) after Breast-conserving surgery (ARCOSEIN study). After a median follow-up of 6.7 years (range, 4.3–9 years), we decided to prospectively evaluate the late effects of these 2 strategies. Methods and Materials: A total of 297 patients from the 5 larger participating institutions were asked to report for a follow-up examination. Seventy-two percent (214 patients) were eligible for evaluation of late toxicity. After Breast-conserving surgery, patients were treated either with sequential treatment with CT first followed by RT (Arm A) or CT administered concurrently with RT (Arm B). In all patients, CT regimen consisted of mitoxantrone (12 mg/m 2 ), 5-FU (500 mg/m 2 ), and cyclophosphamide (500 mg/m 2 ), 6 cycles (Day 1 to Day 21). Conventional RT was delivered to the whole Breast by administration of a 2 Gy per fraction protocol to a total dose of 50 Gy (± boost to the primary tumor bed). The assessment of toxicity was blinded to treatment and was graded by the radiation oncologist, according to the LENT/SOMA scale. Skin pigmentation was also evaluated according to a personal 5-points scoring system (excellent, good, moderate, poor, very poor). Results: Among the 214 evaluable patients, 107 were treated in each arm. The 2 populations were homogeneous for patient, tumor, and treatment characteristics. Subcutaneous fibrosis (SF), telangectasia (T), skin pigmentation (SP), and Breast Atrophy (BA) were significantly increased in Arm B. No statistical difference was observed between the 2 arms of the study concerning Grade 2 or higher pain, Breast edema, or lymphedema. No deaths were caused by late toxicity. Conclusion: After Breast-conserving surgery, the concurrent use of CT with RT is significantly associated with an increase incidence of Grade 2 or greater late side effects.
Robert E. Collins - One of the best experts on this subject based on the ideXlab platform.
-
Unilateral Breast Atrophy.
Plastic and reconstructive surgery, 1995Co-Authors: Harry T. Haramis, Robert E. CollinsAbstract:This represents the only known case of acquired unilateral Breast Atrophy described after previously normal bilateral Breast development. Our patient developed left Breast Atrophy with normal microscopic examination (biopsy) subsequent to infectious mononucleosis. Her reconstruction utilized tissue expansion followed by prosthetic augmentation of the affected side. Despite an exhaustive search, no definitive cause to explain these findings has been found. Perhaps there is some unknown underlying viral etiology that may have further implications for other Breast pathology.
Paola Pinnarò - One of the best experts on this subject based on the ideXlab platform.
-
Impact of Sequencing Radiation Therapy and Chemotherapy on Long-Term Local Toxicity for Early Breast Cancer: Results of a Randomized Study at 15-Year Follow-Up
International journal of radiation oncology biology physics, 2016Co-Authors: Paola Pinnarò, Carolina Giordano, Alessia Farneti, Lidia Strigari, Valeria Landoni, Laura Marucci, Maria Grazia Petrongari, Giuseppe SanguinetiAbstract:Purpose To compare long-term late local toxicity after either concomitant or sequential chemoradiation therapy after Breast-conserving surgery. Methods and Materials From 1997 to 2002, women aged 18 to 75 years who underwent Breast-conserving surgery and axillary dissection for early Breast cancer and in whom CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) chemotherapy was planned were randomized between concomitant and sequential radiation therapy. Radiation therapy was delivered to the whole Breast through tangential fields to 50 Gy in 20 fractions over a period of 4 weeks, followed by an electron boost. Surviving patients were tentatively contacted and examined between March and September 2014. Patients in whom progressive disease had developed or who had undergone further Breast surgery were excluded. Local toxicity (fibrosis, telangiectasia, and Breast Atrophy or retraction) was scored blindly to the treatment received. A logistic regression was run to investigate the effect of treatment sequence after correction for several patient-, treatment-, and tumor-related covariates on selected endpoints. The median time to cross-sectional analysis was 15.7 years (range, 12.0-17.8 years). Results Of 206 patients randomized, 154 (74.8%) were potentially eligible. Of these, 43 (27.9%) refused participation and 4 (2.6%) had been lost to follow-up, and for 5 (3.2%), we could not restore planning data; thus, the final number of analyzed patients was 102. No grade 4 toxicity had been observed, whereas the number of grade 3 toxicity events was low ( P =.013) and the SOMA (Subjective, Objective, Management and Analytic) scale (OR, 3.75; 95% CI, 1.19-11.79; P =.018), as well as grade 2 or 3 Breast Atrophy or retraction (OR, 3.87; 95% CI, 1.42-10.56; P =.008). No effect on telangiectasia was detected. Conclusions At long-term follow-up, concomitant chemoradiation therapy has a detrimental effect on both fibrosis and retraction with an approximately 4-fold increase in the odds of grade 2 or 3 toxicity.